628 related articles for article (PubMed ID: 24762284)
1. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
2. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
3. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
4. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis in real life scenarios.
Fischer K; Konkle B; Broderick C; Kessler CM
Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
[TBL] [Abstract][Full Text] [Related]
6. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
7. Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
von Mackensen S; Kalnins W; Krucker J; Weiss J; Miesbach W; Albisetti M; Pabinger I; Oldenburg J
Haemophilia; 2017 Jul; 23(4):566-574. PubMed ID: 28370896
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
10. Emerging drugs for hemophilia B.
Mannucci PM; Franchini M
Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
[TBL] [Abstract][Full Text] [Related]
11. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
12. The benefits of prophylaxis in patients with hemophilia B.
Castaman G
Expert Rev Hematol; 2018 Aug; 11(8):673-683. PubMed ID: 29909699
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis in haemophilic children.
Liesner RJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Antunes SV; Tangada S; Stasyshyn O; Mamonov V; Phillips J; Guzman-Becerra N; Grigorian A; Ewenstein B; Wong WY
Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
[TBL] [Abstract][Full Text] [Related]
15. Extended half-life clotting factor concentrates: results from published clinical trials.
Young G; Mahlangu JN
Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
[TBL] [Abstract][Full Text] [Related]
16. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
17. The availability of new drugs for hemophilia treatment.
Morfini M; Marchesini E
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):721-738. PubMed ID: 32515633
[TBL] [Abstract][Full Text] [Related]
18. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
19. The natural history of mild haemophilia: a 30-year single centre experience.
Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
[TBL] [Abstract][Full Text] [Related]
20. BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.
Windyga J; Abbuehl BE; Hafeman AE
Expert Rev Hematol; 2014 Jun; 7(3):333-42. PubMed ID: 24832133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
